Narrow search
Showing 1 - 10 of 1,437
Cover Image
Generic Entry, Reformulations and Promotion of SSRIs in the US
Huskamp, Haiden A.; Donohue, Julie M.; Koss, Catherine; … - In: PharmacoEconomics 26 (2008) 7, pp. 603-616
and direct-to-consumer advertising [DTCA], and the retail value of free samples distributed in physician offices) for …
Persistent link: https://www.econbiz.de/10005243133
Cover Image
Does Direct-to-Consumer Advertising of Antidepressants Lead to a Net Social Benefit?
Jureidini, Jon; Mintzes, Barbara; Raven, Melissa - In: PharmacoEconomics 26 (2008) 7, pp. 557-566
Persistent link: https://www.econbiz.de/10005449048
Cover Image
Costs and Benefits of Direct-to-Consumer Advertising: The Case of Depression
Block, Adam E. - In: PharmacoEconomics 25 (2007) 6, pp. 511-521
Background: Direct-to-consumer advertising (DTCA) is legal in the US and New Zealand, but illegal in the rest of the …
Persistent link: https://www.econbiz.de/10005449192
Cover Image
The Author's Reply
Block, Adam E. - In: PharmacoEconomics 26 (2008) 7, pp. 567-568
Persistent link: https://www.econbiz.de/10005449213
Cover Image
Direct-to-Consumer Promotion of Prescription Drugs: Economic Implications for Patients, Payers and Providers
Findlay, Steven D. - In: PharmacoEconomics 19 (2001) 2, pp. 109-119
trend, attention has recently focused on the role played by the marketing, promotion and advertising of pharmaceuticals, in … particular direct-to-consumer (DTC) advertising. In 1997, the US Food and Drug Administration (FDA) issued a `guidance' on such … newspapers have proliferated rapidly. Pharmaceutical companies spent $US1.8 billion on DTC advertising in 1999, a 40% increase …
Persistent link: https://www.econbiz.de/10005590378
Cover Image
Economic Content in Medical Journal Advertisements for Medical Devices and Prescription Drugs
Ackerly, D. Clay.; Glickman, Seth W.; Schulman, Kevin A. - In: PharmacoEconomics 28 (2010) 5, pp. 429-438
.99). For pharmaceuticals, price claims declined significantly (15.7-4.2%; p < 0.01) and market share claims increased (2 …
Persistent link: https://www.econbiz.de/10008620565
Cover Image
Do Productivity Costs Matter?: The Impact of Including Productivity Costs on the Incremental Costs of Interventions Targeted at Depressive Disorders
Krol, Marieke; Papenburg, Joc; Koopmanschap, Marc; … - In: PharmacoEconomics 29 (2011) 7, pp. 601-619
Background:Background: When guidelines for health economic evaluations prescribe that a societal perspective should be adopted, productivity costs should be included. However, previous research suggests that, in practice, productivity costs are often neglected. This may considerably bias the...
Persistent link: https://www.econbiz.de/10011005068
Cover Image
Is There a Role for Pharmacoeconomics in Developing Countries?
Harper, Jonathan R. - In: PharmacoEconomics 29 (2011) 5, pp. 435-436
Persistent link: https://www.econbiz.de/10011005069
Cover Image
Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer: A Systematic Review
Bongers, Mathilda L.; Coupé, Veerle M.H. Coup; Jansma, … - In: PharmacoEconomics 30 (2012) 1, pp. 17-34
In past decades, studies focusing on new chemotherapeutic agents for patients with inoperable non-small-cell lung cancer have reported only modest gains in survival. These health gains are achieved at considerable cost, but economic evidence is lacking on superiority of one agent in terms of...
Persistent link: https://www.econbiz.de/10011005070
Cover Image
Cost of Illness of Cystic Fibrosis in Germany: Results from a Large Cystic Fibrosis Centre
Heimeshoff, Mareike; Hollmeyer, Helge; Schreyogg, Jonas … - In: PharmacoEconomics 30 (2012) 9, pp. 763-777
Background:Background: Cystic fibrosis (CF) is the most common life-shortening genetic disorder among Whites worldwide. Because many of these patients experience chronic endobronchial colonization and have to take antibiotics and be treated as inpatients, societal costs of CF may be high. As the...
Persistent link: https://www.econbiz.de/10011005071